Operating Lease, Right-of-Use Asset of Fulcrum Therapeutics, Inc. from 31 Dec 2021 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Fulcrum Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
  • Fulcrum Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $4,241,000, a 25% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Fulcrum Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,241,000 -$1,443,000 -25% 31 Dec 2025 10-K 24 Feb 2026 2025 FY
Q3 2025 $4,614,000 -$1,410,000 -23% 30 Sep 2025 10-Q 29 Oct 2025 2025 Q3
Q2 2025 $4,979,000 -$1,378,000 -22% 30 Jun 2025 10-Q 29 Jul 2025 2025 Q2
Q1 2025 $5,335,000 -$1,347,000 -20% 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $5,684,000 -$1,492,000 -21% 31 Dec 2024 10-K 24 Feb 2026 2025 FY
Q3 2024 $6,024,000 -$1,637,000 -21% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 $6,357,000 -$1,780,000 -22% 30 Jun 2024 10-Q 31 Jul 2024 2024 Q2
Q1 2024 $6,682,000 -$1,922,000 -22% 31 Mar 2024 10-Q 13 May 2024 2024 Q1
Q4 2023 $7,176,000 -$1,887,000 -21% 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $7,661,000 -$1,852,000 -19% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $8,137,000 -$1,817,000 -18% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q1
Q1 2023 $8,604,000 -$1,784,000 -17% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $9,063,000 +$9,063,000 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $9,513,000 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $9,954,000 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $10,388,000 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $0 31 Dec 2021 10-K/A 26 Jun 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.